The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Targeting the DNA Damage Response in Cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citationA DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917
Cited by
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
Blackford, A. N., & Jackson, S. P. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.05.015 · Cited by 1,961
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Deubiquitylating enzymes and drug discovery: emerging opportunities
Harrigan, J. A., Jacq, X., Martin, N. M., & Jackson, S. P. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.152 · Cited by 940
Huang, R., & Zhou, P.-K. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00648-7 · Cited by 907
The control of DNA repair by the cell cycle
Hustedt, N., & Durocher, D. (2017) · Nature Cell Biology · doi:10.1038/ncb3452 · Cited by 738
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Pommier, Y., O’Connor, M. J., & de Bono, J. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9246 · Cited by 739
Self-citationDNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
A Genetic Map of the Response to DNA Damage in Human Cells
Olivieri, M., Cho, T., Álvarez-Quilón, A., Li, K., Schellenberg, M. J., Zimmermann, M., Hustedt, N., Rossi, S. E., Adam, S., Melo, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.040 · Cited by 551
Orth, M., Metzger, P., Gerum, S., Mayerle, J., Schneider, G., Belka, C., Schnurr, M., & Lauber, K. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1345-6 · Cited by 490
N6-methyladenosine links RNA metabolism to cancer progression
Dai, D., Wang, H., Zhu, L., Jin, H., & Wang, X. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0129-x · Cited by 473
Mäder, P., & Kattner, L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00960 · Cited by 438
Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis
Reiter, R., Rosales-Corral, S., Tan, D.-X., Acuna-Castroviejo, D., Qin, L., Yang, S.-F., & Xu, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040843 · Cited by 433
Cruz, C., Castroviejo-Bermejo, M., Gutiérrez-Enríquez, S., Llop-Guevara, A., Ibrahim, Y. H., Gris-Oliver, A., Bonache, S., Morancho, B., Bruna, A., Rueda, O. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy099 · Cited by 433
Self-citationYazinski, S. A., Comaills, V., Buisson, R., Genois, M.-M., Nguyen, H. D., Ho, C. K., Todorova Kwan, T., Morris, R., Lauffer, S., Nussenzweig, A., et al. (2017) · Genes & Development · doi:10.1101/gad.290957.116 · Cited by 395
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Cortesi, L., Rugo, H. S., & Jackisch, C. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00796-4 · Cited by 393
DNA Repair Pathways in Cancer Therapy and Resistance
Li, L.-Y., Guan, Y.-D., Chen, X.-S., Yang, J.-M., & Cheng, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.629266 · Cited by 383
Improving radiotherapy in cancer treatment: Promises and challenges
Chen, H. H. W., & Kuo, M. T. (2017) · Oncotarget · doi:10.18632/oncotarget.18409 · Cited by 372
Cell Death in the Origin and Treatment of Cancer
Strasser, A., & Vaux, D. L. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.014 · Cited by 370
Natural compounds and combination therapy in colorectal cancer treatment
Rejhová, A., Opattová, A., Čumová, A., Slíva, D., & Vodička, P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.039 · Cited by 364
Targeting replication stress in cancer therapy
da Costa, A. A. B. A., Chowdhury, D., Shapiro, G. I., D’Andrea, A. D., & Konstantinopoulos, P. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00558-5 · Cited by 359
Thorsell, A.-G., Ekblad, T., Karlberg, T., Löw, M., Pinto, A. F., Trésaugues, L., Moche, M., Cohen, M. S., & Schüler, H. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00990 · Cited by 358
Foote, K. M., Nissink, J. W. M., McGuire, T., Turner, P., Guichard, S., Yates, J. W. T., Lau, A., Blades, K., Heathcote, D., Odedra, R., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01187 · Cited by 332
Fok, J. H. L., Ramos-Montoya, A., Vazquez-Chantada, M., Wijnhoven, P. W. G., Follia, V., James, N., Farrington, P. M., Karmokar, A., Willis, S. E., Cairns, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12836-9 · Cited by 331
Self-citationPARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Pilié, P. G., Gay, C. M., Byers, L. A., O'Connor, M. J., & Yap, T. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0968 · Cited by 330
Self-citationDurant, S. T., Zheng, L., Wang, Y., Chen, K., Zhang, L., Zhang, T., Yang, Z., Riches, L., Trinidad, A. G., Fok, J. H. L., et al. (2018) · Science Advances · doi:10.1126/sciadv.aat1719 · Cited by 309
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Murai, J., Feng, Y., Yu, G. K., Ru, Y., Tang, S.-W., Shen, Y., & Pommier, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12266 · Cited by 297
Bang, Y.-J., Xu, R.-H., Chin, K., Lee, K.-W., Park, S. H., Rha, S. Y., Shen, L., Qin, S., Xu, N., Im, S.-A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30682-4 · Cited by 296
Nuclear Acetyl-CoA Production by ACLY Promotes Homologous Recombination
Sivanand, S., Rhoades, S., Jiang, Q., Lee, J. V., Benci, J., Zhang, J., Yuan, S., Viney, I., Zhao, S., Carrer, A., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.008 · Cited by 295
The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance
Park, S.-Y., Lee, C.-J., Choi, J.-H., Kim, J.-H., Kim, J.-W., Kim, J.-Y., & Nam, J.-S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1405-7 · Cited by 292
Penson, R. T., Valencia, R. V., Cibula, D., Colombo, N., Leath, C. A., Bidziński, M., Kim, J.-W., Nam, J. H., Madry, R., Hernández, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02745 · Cited by 291
The DNA damage-induced cell death response: a roadmap to kill cancer cells
Matt, S., & Hofmann, T. G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2130-4 · Cited by 288
Targeted Therapies in Advanced Gastric Cancer
Patel, T. H., & Cecchini, M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00774-4 · Cited by 282
Mechanisms of DNA–protein crosslink repair
Stingele, J., Bellelli, R., & Boulton, S. J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.56 · Cited by 281
Genetic etiology of oral cancer
Ali, J., Sabiha, B., Jan, H. U., Haider, S. A., Khan, A. A., & Ali, S. S. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.05.004 · Cited by 256
Kindler, H. L., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J. O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01604 · Cited by 244
Patterns of Early p21 Dynamics Determine Proliferation-Senescence Cell Fate after Chemotherapy
Hsu, C.-H., Altschuler, S. J., & Wu, L. F. (2019) · Cell · doi:10.1016/j.cell.2019.05.041 · Cited by 181
Murai, J., Thomas, A., Miettinen, M., & Pommier, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.009 · Cited by 172
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
George, A., Kaye, S., & Banerjee, S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.191 · Cited by 158
Sun, H., Cai, H., Xu, C., Zhai, H., Lux, F., Xie, Y., Feng, L., Du, L., Liu, Y., Sun, X., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01654-9 · Cited by 86
Ha, D.-H., Min, A., Kim, S., Jang, H., Kim, S. H., Kim, H.-J., Ryu, H. S., Ku, J.-L., Lee, K.-H., & Im, S.-A. (2020) · Scientific Reports · doi:10.1038/s41598-020-66018-5 · Cited by 78
Schoetz, U., Klein, D., Hess, J., Shnayien, S., Spoerl, S., Orth, M., Mutlu, S., Hennel, R., Sieber, A., Ganswindt, U., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04454-5 · Cited by 74
Moreno-Lama, L., Galindo-Campos, M. A., Martínez, C., Comerma, L., Vazquez, I., Vernet-Tomas, M., Ampurdanés, C., Lutfi, N., Martin-Caballero, J., Dantzer, F., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1175-x · Cited by 29
Fukuda, K., Takeuchi, S., Arai, S., Nanjo, S., Sato, S., Kotani, H., Kita, K., Nishiyama, A., Sakaguchi, H., Ohtsubo, K., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101578 · Cited by 24
DNA Repair Capacity and Response to Treatment of Colon Cancer
Vodicka, P., Vodenkova, S., Buchler, T., & Vodickova, L. (2019) · Pharmacogenomics · doi:10.2217/pgs-2019-0070 · Cited by 19
Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer
Iovanna, J. (2021) · Translational Oncology · doi:10.1016/j.tranon.2020.100965 · Cited by 18
Bar, S., Hilsabeck, T. A. U., Pattavina, B., López-Domínguez, J. A., Basisty, N., Bons, J., Watson, M., Schilling, B., Campisi, J., Kapahi, P., et al. (2025) · Aging · doi:10.18632/aging.206224 · Cited by 3
Metadata
- Authors
- O’Connor, M. J.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 60
- Issue
- 4
- Pages
- 547-560
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W2173456459
- Cited by
- 1,518
- References
- 116
- FWCI
- 34.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.